BENDAMUSTINE HYDROCHLORIDE
| Brand name | BENDEKA |
|---|---|
| Active ingredient | BENDAMUSTINE HYDROCHLORIDE |
| Strength | 100MG/4ML (25MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | December 2015 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9144568 | March 2033 | use U-1542 |
| 10052385 | March 2033 | use U-1971 |
| 9597399 | March 2033 | use U-1971 |
| 9034908 | March 2033 | use U-1542 |
| 9597397 | March 2033 | use U-1971 |
| 9572887 | March 2033 | use U-1971 |
| 9579384 | March 2033 | use U-1972 |
| 9000021 | March 2033 | use U-1542 |
| 9597398 | March 2033 | use U-1971 |
| 8609707 | August 2031 | product |
| 10010533 | January 2031 | product |
| 12350257 | January 2031 | product |
| 9572797 | January 2031 | use U-1972 |
| 9265831 | January 2031 | product |
| 11103483 | January 2031 | product |
| 11844783 | January 2031 | use U-1971 |
| 9572796 | January 2031 | product |
| 12138248 | January 2031 | product |
| 11872214 | January 2031 | product |
| 8791270 | January 2026 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.